A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Summary

To evaluate the safety and preliminary efficacy of HRS-4642 in combination with antineoplastic agents in subjects with advanced solid tumors with KRAS G12D mutations, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).

Timeline

Start

2024-08-09

Primary completion

2027-03

Completion

2027-07

Publications

• Cui J, Jiang K, Li W, Ni S, Zong H, Du J, He Y, Liu Z, Kong G, Zhang Y, Li X, Han H, Yao F, Chen Y, Zhou M, Wang L. KRAS-G12D inhibitor HRS-4642 plus chemotherapy in advanced KRASG12D-mutant pancreatic cancer: a phase 1b/2 trial. Nat Med. 2026 Jul 9. doi: 10.1038/s41591-026-04538-9. Online ahead of print.

Drugs

Indications